Publications

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Gerke T, Beltran H, Wang X, Lee G-SMary, Sboner A, R Karnes J, Klein EA, Davicioni E, Yousefi K, Ross AE et al..  2019.  Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.. Cancer Epidemiol Biomarkers Prev. 28(3):584-590.

Gerke T, Beltran H, Wang X, Lee G-SMary, Sboner A, R Karnes J, Klein EA, Davicioni E, Yousefi K, Ross AE et al..  2019.  Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.. Cancer Epidemiol Biomarkers Prev. 28(3):584-590.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Guo H, Ci X, Ahmed M, Hua JTony, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E et al..  2019.  ONECUT2 is a driver of neuroendocrine prostate cancer.. Nat Commun. 10(1):278.

Guo H, Ci X, Ahmed M, Hua JTony, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E et al..  2019.  ONECUT2 is a driver of neuroendocrine prostate cancer.. Nat Commun. 10(1):278.

Guo H, Ci X, Ahmed M, Hua JTony, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E et al..  2019.  ONECUT2 is a driver of neuroendocrine prostate cancer.. Nat Commun. 10(1):278.

Guo H, Ci X, Ahmed M, Hua JTony, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E et al..  2019.  ONECUT2 is a driver of neuroendocrine prostate cancer.. Nat Commun. 10(1):278.

Guo H, Ci X, Ahmed M, Hua JTony, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E et al..  2019.  ONECUT2 is a driver of neuroendocrine prostate cancer.. Nat Commun. 10(1):278.

Nowak DG, Katsenelson KCohen, Watrud KE, Chen M, Mathew G, D'Andrea VD, Lee MF, Swamynathan MMosur, Casanova-Salas I, Jibilian MC et al..  2019.  The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.. J Cell Biol. 218(6):1943-1957.

Boehm KMichael, Bhinder B, Raja VJoseph, Dephoure N, Elemento O.  2019.  Predicting peptide presentation by major histocompatibility complex class I: an improved machine learning approach to the immunopeptidome.. BMC Bioinformatics. 20(1):7.

Boehm KMichael, Bhinder B, Raja VJoseph, Dephoure N, Elemento O.  2019.  Predicting peptide presentation by major histocompatibility complex class I: an improved machine learning approach to the immunopeptidome.. BMC Bioinformatics. 20(1):7.

Choudhury AD, Beltran H.  2019.  Retinoblastoma Loss in Cancer: Casting a Wider Net.. Clin Cancer Res. 25(14):4199-4201.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2018.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2018.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2018.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.